Clevergene scales up genomics capacity to expand its genetic diagnostics and discovery genomics offerings

Our Bureau

Clevergene Biocorp, a Bangalore based genomics company with unrivalled discovery genomics and genetic diagnostics capabilities, has increased its testing capacity to over 1 lakh annual tests, with the installation of the latest Illumina NovaSeq 6000 DNA sequencing platform, the most advanced DNA sequencer in the world. This puts Clevergene amid an elite club of organisations around the world that can analyse tens of thousands of human genomes.

The added capacity will open new horizons for highly powered experiments at the depth required to discover rare genetic events. With this addition, Clevergene will be able to explore new horizons to widen its discovery genomics offerings by introducing applications such as single cell gene expression, genome deep sequencing etc, that requires large volumes of DNA sequence data.  Clevergene is also aiming at leading genetic diagnostics with a focus to provide diagnosis for rare and difficult to diagnose genetic ailments.

Speaking on this latest addition Tony Jose, Co-Founder & CEO of Clevergene said, “Our primary intention behind this investment is to scale up our genetic diagnostics portfolio and make available comprehensive genetic diagnosis to the millions of patients suffering with genetic ailments. We are also expanding our discovery genomics offerings to Europe and North America.”

The addition of this critical piece of infrastructure is great news for top life science research institutions, speciality hospitals and diagnostics companies who have been looking for a partner in Genomics with capabilities in high-throughput sequencing and deep tech genome analysis.

This investment has augmented Clevergene’s already strong testing abilities and puts them in a strong position to partner global discovery genomics projects.


Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Approval of mixing and matching of COVID booster shots by FDA is yet another confirmation of efficacy of vaccine cocktail approach pioneered by the Russian Sputnik V vaccine

Following the decision by the U.S. Food and Drug Administration allowing individuals to receive booster shots that are different from their first COVID-19 vaccine doses, the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) reiterates that the heterologous boosting approach pioneered by the Russian Sputnik V vaccine is one […]

Subscribe Now